HLS Therapeutics (TSX:HLS) COGS-to-Revenue : 0.14 (As of Mar. 2024)

View and export this data going back to 1959. Start your Free Trial

What is HLS Therapeutics COGS-to-Revenue?

HLS Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2024 was C$2.40 Mil. Its Revenue for the three months ended in Mar. 2024 was C$16.88 Mil.

HLS Therapeutics's COGS to Revenue for the three months ended in Mar. 2024 was 0.14.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. HLS Therapeutics's Gross Margin % for the three months ended in Mar. 2024 was 85.78%.

HLS Therapeutics COGS-to-Revenue Historical Data

The historical data trend for HLS Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics COGS-to-Revenue Chart

HLS Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.04

0.06

0.07

0.08

0.12

HLS Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.10	0.11	0.12	0.16	0.14

HLS Therapeutics COGS-to-Revenue Calculation

HLS Therapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	10.228	/	84.62
	=	0.12

HLS Therapeutics's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	2.401	/	16.883
	=	0.14

HLS Therapeutics (TSX:HLS) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

HLS Therapeutics's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	2.401 / 16.883
	=	85.78 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

HLS Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

HLS Therapeutics (TSX:HLS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (TSX:HLS) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

HLTRF:USA

Address

10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W6L2

Website

https://www.hlstherapeutics.com

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, Trinomia, and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of the world.

Executives

Polar Asset Management Partners Inc.

10% Security Holder

HLS Therapeutics (TSX:HLS) Headlines

No Headlines